MX420195B - Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos - Google Patents

Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos

Info

Publication number
MX420195B
MX420195B MX2022000939A MX2022000939A MX420195B MX 420195 B MX420195 B MX 420195B MX 2022000939 A MX2022000939 A MX 2022000939A MX 2022000939 A MX2022000939 A MX 2022000939A MX 420195 B MX420195 B MX 420195B
Authority
MX
Mexico
Prior art keywords
methods
macrocyclic compounds
sting agonists
compounds
disclosed
Prior art date
Application number
MX2022000939A
Other languages
English (en)
Other versions
MX2022000939A (es
Inventor
Amit Kumar Das
Deepak Sahebrao Walke
Ganesh Rajaram Jadhav
Moloy Banerjee
Navnath Popat Karche
Nishant Ramnivasji Gupta
Rajender Kumar Kamboj
Smita Aditya Bhoskar
Vaibhav Madhukar Kalhapure
Venkata P Palle
Vidya Ramdas
Vinod Popatrao Vyavahare
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72422197&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX420195(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MX2022000939A publication Critical patent/MX2022000939A/es
Publication of MX420195B publication Critical patent/MX420195B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se desvelan compuestos macrocíclicos que tienen la Fórmula general (I) o (II) y sus formas tautoméricas, estereoisómeros, sales farmacéuticamente aceptables, hidratos, solvatos y profármacos de los mismos y su combinación con un medicamento adecuado, procesos correspondientes para la síntesis, y composiciones farmacéuticas y usos de compuestos desvelados en el presente documento. (fórmulas)
MX2022000939A 2019-07-22 2020-07-22 Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos MX420195B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201921029556 2019-07-22
IN201921051086 2019-12-10
IN202021003961 2020-01-29
PCT/IB2020/056875 WO2021014365A1 (en) 2019-07-22 2020-07-22 Macrocyclic compounds as sting agonists and methods and uses thereof

Publications (2)

Publication Number Publication Date
MX2022000939A MX2022000939A (es) 2022-04-06
MX420195B true MX420195B (es) 2025-02-10

Family

ID=72422197

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000939A MX420195B (es) 2019-07-22 2020-07-22 Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos

Country Status (33)

Country Link
US (1) US12479858B2 (es)
EP (1) EP4004002B1 (es)
JP (1) JP7592689B2 (es)
KR (1) KR20220035955A (es)
CN (1) CN114174303B (es)
AU (1) AU2020319058B2 (es)
BR (1) BR112022001125A2 (es)
CA (1) CA3147397A1 (es)
CL (1) CL2022000145A1 (es)
CO (1) CO2022001814A2 (es)
CR (1) CR20220029A (es)
DK (1) DK4004002T3 (es)
EC (1) ECSP22005485A (es)
ES (1) ES2989915T3 (es)
FI (1) FI4004002T3 (es)
GE (2) GEP20247627B (es)
HR (1) HRP20241222T1 (es)
HU (1) HUE068456T2 (es)
IL (1) IL289740B2 (es)
LT (1) LT4004002T (es)
MA (1) MA56674B1 (es)
MX (1) MX420195B (es)
PE (1) PE20220937A1 (es)
PH (1) PH12022550175A1 (es)
PL (1) PL4004002T3 (es)
PT (1) PT4004002T (es)
RS (1) RS66126B1 (es)
SA (1) SA522431429B1 (es)
SI (1) SI4004002T1 (es)
SM (1) SMT202400399T1 (es)
UA (1) UA129653C2 (es)
WO (1) WO2021014365A1 (es)
ZA (1) ZA202201375B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL269535B2 (en) 2017-03-29 2024-11-01 Ligachem Biosciences Inc Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same
JP7240554B2 (ja) 2019-07-22 2023-03-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性気道疾患又は線維性疾患の治療のためのオートタキシン（ａｔｘ）モジュレーターとしてのｎ－メチル，１－（６－（メトキシ）ピリダジン－３－イル）アミン誘導体
US11155567B2 (en) 2019-08-02 2021-10-26 Mersana Therapeutics, Inc. Sting agonist compounds and methods of use
MY210304A (en) 2020-04-02 2025-09-10 Mersana Therapeutics Inc Antibody drug conjugates comprising sting agonists
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
AU2022208054A1 (en) * 2021-01-15 2023-07-27 Seagen Inc. Immunomodulatory antibody-drug conjugates
CN117203194A (zh) * 2021-03-30 2023-12-08 北京加科思新药研发有限公司 用作sting激动剂的新型化合物及其用途
CN120513246A (zh) * 2022-12-22 2025-08-19 阿库勒斯治疗私人有限公司 用于调节sting的苯并咪唑衍生物
WO2025012057A1 (en) * 2023-07-07 2025-01-16 F. Hoffmann-La Roche Ag Macrocycles for the treatment of autoimmune disease
AR133266A1 (es) * 2023-07-19 2025-09-10 Hoffmann La Roche Macrociclos para el tratamiento de enfermedades autoinmunitarias
CN119490423A (zh) * 2023-08-15 2025-02-21 沈阳中化农药化工研发有限公司 一种制备2-氟-3-氨基苯甲酸及其酯类化合物的方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20010395A1 (it) 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
AR046959A1 (es) 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
US7488736B2 (en) 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
ATE504565T1 (de) 2005-10-07 2011-04-15 Exelixis Inc Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
RU2008152195A (ru) 2006-06-15 2010-07-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) 2-анилино-4-(гетероциклил)аминопиримидины, как ингибиторы протеинкиназы с-альфа
WO2008090570A1 (en) 2007-01-25 2008-07-31 Panacea Biotec Ltd Novel antimicrobials
TW201000447A (en) 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
WO2011091446A1 (en) * 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
EP2651926A4 (en) * 2010-12-15 2014-07-09 Abbvie Inc ANTI-VIRAL COMPOUNDS
WO2014104272A1 (ja) 2012-12-28 2014-07-03 日本臓器製薬株式会社 ケイ皮酸アミド誘導体
CA2950033A1 (en) * 2014-06-04 2015-12-10 Glaxosmithkline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
US20180147187A1 (en) 2015-01-12 2018-05-31 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2017011920A1 (en) 2015-07-22 2017-01-26 The Royal Institution For The Advancement Of Learning/Mcgill University Compounds and uses thereof in the treatment of cancers and other medical conditions
SI3440076T1 (sl) 2016-04-07 2022-09-30 Glaxosmithkline Intellectual Property Development Limited Heterociklični amidi uporabni kot proteinski modulatorji
CN109563081A (zh) 2016-04-07 2019-04-02 葛兰素史克知识产权开发有限公司 可用作蛋白调节剂的杂环酰胺类
EP3483158B1 (en) 2016-05-27 2022-08-10 Hangzhou Innogate Pharma Co., Ltd. Heterocyclic compound serving as fgfr4 inhibitor
EA036338B1 (ru) * 2017-02-22 2020-10-28 Глэксосмитклайн Интеллекчуал Проперти Девелопмент Лимитед Гетероциклические амиды, пригодные в качестве модуляторов белков
JP2020524717A (ja) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの小分子調節因子
WO2018234808A1 (en) 2017-06-22 2018-12-27 Curadev Pharma Limited Small molecule modulators of human sting
US20200172483A1 (en) 2017-06-22 2020-06-04 Curadev Pharma Limited Heterocyclic small molecule modulators of human sting
WO2019023635A1 (en) 2017-07-27 2019-01-31 Stingray Therapeutics, Inc. SUBSTITUTED 3 H-IMIDAZO (4,5-C) PYRIDINE AND 1H-PYRROLO (2,3-C) PYRIDINE SERIES OF A NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR A GENE MODULATOR INTERFERON (STING) AS IMMUNOTHERAPEUTIC AGENTS AGAINST CANCER
US11285131B2 (en) 2017-08-04 2022-03-29 Merck Sharp & Dohme Corp. Benzo[b]thiophene STING agonists for cancer treatment
JP2020529421A (ja) 2017-08-04 2020-10-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ
WO2019069270A1 (en) * 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited GENERATOR STIMULATOR MODULATORS (STING) INTERFERON
JP2020536106A (ja) * 2017-10-05 2020-12-10 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｈｉｖの処置に有用なインターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質
WO2020132582A1 (en) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Sting agonists and uses thereof
US20220144852A1 (en) * 2019-03-28 2022-05-12 Lupin Limited Macrocyclic compounds as sting agonists

Also Published As

Publication number Publication date
PT4004002T (pt) 2024-10-07
HRP20241222T1 (hr) 2024-12-06
CO2022001814A2 (es) 2022-04-29
CN114174303A (zh) 2022-03-11
AU2020319058A1 (en) 2022-02-17
UA129653C2 (uk) 2025-06-25
ZA202201375B (en) 2022-09-28
BR112022001125A2 (pt) 2022-03-15
ES2989915T3 (es) 2024-11-28
GEAP202415883A (en) 2024-02-12
AU2020319058B2 (en) 2025-10-02
MX2022000939A (es) 2022-04-06
PL4004002T3 (pl) 2024-11-18
CA3147397A1 (en) 2021-01-28
IL289740B2 (en) 2025-10-01
KR20220035955A (ko) 2022-03-22
JP7592689B2 (ja) 2024-12-02
WO2021014365A1 (en) 2021-01-28
GEP20247627B (en) 2024-05-27
EP4004002A1 (en) 2022-06-01
IL289740A (en) 2022-03-01
CN114174303B (zh) 2024-06-25
SMT202400399T1 (it) 2024-11-15
SI4004002T1 (sl) 2024-12-31
IL289740B1 (en) 2025-06-01
MA56674B1 (fr) 2024-09-30
SA522431429B1 (ar) 2024-11-11
CR20220029A (es) 2022-03-14
ECSP22005485A (es) 2022-02-25
US20220289763A1 (en) 2022-09-15
CL2022000145A1 (es) 2022-09-09
DK4004002T3 (da) 2024-09-30
LT4004002T (lt) 2024-10-25
PH12022550175A1 (en) 2022-11-14
EP4004002B1 (en) 2024-07-10
RS66126B1 (sr) 2024-11-29
PE20220937A1 (es) 2022-05-31
US12479858B2 (en) 2025-11-25
FI4004002T3 (fi) 2024-10-04
HUE068456T2 (hu) 2024-12-28
JP2022541330A (ja) 2022-09-22

Similar Documents

Publication Publication Date Title
MX420195B (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
CY1124404T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 και μεθοδοι χρησης αυτων
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
CR20220251A (es) Nuevos derivados de metilquinazolinona
CU20200070A7 (es) Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de quinasa dependientes de ciclina
CR20220234A (es) Degradadores de moléculas pequeñas de helios y procedimientos de uso
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
MX2020007265A (es) Derivados de rapamicina.
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
EA201691302A1 (ru) Новые гетероциклические соединения
PH12021552263A1 (en) Macrocyclic compounds as sting agonists
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
UY40230A (es) Macrociclos con grupos P2’ heterocíclicos como inhibidores del factor XIa y composiciones farmacéuticas que los comprenden
MX2019008435A (es) Inhibidores selectivos de jak1.
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
UY37182A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
ECSP099722A (es) Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
MX2021007247A (es) Derivados de rapamicina.
CY1123185T1 (el) Παραγωγα ινδολιου
MX2022000103A (es) Compuestos para el tratamiento de trastornos oculares.
MX2022006266A (es) Derivados macrociclicos de panteteina y usos de los mismos.